Searchable abstracts of presentations at key conferences on reproductive biology and medicine

ra0001p144 | (1) | WCRB2014

Etoposide has a detrimental impact on mouse ovarian development when exposure occurs during early meiotic prophase

Johnston Zoe C , Stefansdottir Agnes , Adams Ian , Spears Norah

Introduction: The use of the chemotherapeutic agent etoposide in pregnancy is considered to be relatively safe during the second and third trimesters. However, the drug does have detrimental effects on oocytes undergoing meiosis II. Similar effects on oocytes in meiosis I may have a clinical impact on the fertility of women exposed to the drug in utero, during critical stages of ovarian development. This study aims to examine the effects of etoposide exposure during e...

ra0003o014 | SRF Post-Doctoral Prize Session | SRF2016

Etoposide results in follicle loss in the fetal mouse ovary, but does not block the ability of oocytes to progress through prophase I of meiosis

Stefansdottir Agnes , Johnston Zoe , Powles-Glover Nicola , Anderson Richard , Adams Ian , Spears Norah

Introduction: The chemotherapy agent etoposide is a topoisomerase II (topo II) inhibitor, and is considered safe to administer during pregnancy. However, assessment of its effects on the developing ovary, when germ cells are undergoing initiation of meiosis and forming follicles, has been limited. We have investigated this using ovarian tissue culture.Methods: E13.5 mouse ovaries were cultured for 12 days on an agar block, with etoposide added for the fi...